Metotrexato Mylan (Methotrexate Sodium)

Methotrexate blocks the enzyme dihydrofolate reductase, limiting the production of tetrahydrofolate needed for DNA synthesis. This reduces the proliferation of immune cells involved in inflammation and the replication of malignant lymphoblasts, providing both immunosuppressive and anticancer effects.

The dosage of Metotrexato Mylan is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Only a qualified healthcare professional can determine the appropriate dose and schedule.

Methotrexate is classified as contraindicated during pregnancy because of its known teratogenic potential. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding; the drug is generally avoided, and a risk‑benefit assessment should be performed by the prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Compared with biologic agents such as TNF‑alpha inhibitors, methotrexate is a small‑molecule immunosuppressant that is less expensive and can be used as monotherapy or in combination. However, biologics may offer faster symptom control for some patients, while methotrexate carries a distinct safety profile that includes hepatic and hematologic monitoring.

Metotrexato Mylan should be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and do not freeze or shake the vial. If a temporary temperature excursion occurs, consult the supplier before use.

The medication is supplied as a sterile solution for subcutaneous injection. It is typically administered by a healthcare professional or trained patient using a pre‑filled syringe or needle‑free device, following aseptic technique and the dosing schedule prescribed by the clinician.

Key serious risks include severe liver toxicity (potential fibrosis or cirrhosis), bone marrow suppression leading to pancytopenia, and pulmonary fibrosis. Patients should be monitored regularly for liver enzyme elevations, blood count changes, and respiratory symptoms, and any concerning findings should prompt immediate medical evaluation.

Methotrexate is contraindicated in individuals with severe hepatic impairment, active uncontrolled infections, known hypersensitivity to methotrexate or its excipients, and in pregnant women. Caution is also advised for patients with renal insufficiency, immunodeficiency, or those receiving other myelosuppressive agents.